FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897747244> ?p ?o ?g. }

• W2897747244 endingPage "975" @default.
• W2897747244 startingPage "967" @default.
• W2897747244 abstract "To evaluate the incidence of anti-drug antibody (ADA) occurrences and ADA-related risk factors under adalimumab and infliximab treatment in rheumatoid arthritis (RA) patients. The study combined retrospective cohorts from the ABIRISK project totaling 366 RA patients treated with adalimumab (n = 240) or infliximab (n = 126), 92.4% of them anti-TNF naive (n = 328/355) and 96.6% of them co-treated with methotrexate (n = 341/353) with up to 18 months follow-up. ADA positivity was measured by enzyme‐linked immunosorbent assay. The cumulative incidence of ADA was estimated, and potential bio-clinical factors were investigated using a Cox regression model on interval-censored data. ADAs were detected within 18 months in 19.2% (n = 46) of the adalimumab-treated patients and 29.4% (n = 37) of the infliximab-treated patients. The cumulative incidence of ADA increased over time. In the adalimumab and infliximab groups, respectively, the incidence was 15.4% (5.2–20.2) and 0% (0–5.9) at 3 months, 17.6% (11.4–26.4) and 0% (0–25.9) at 6 months, 17.7% (12.6–37.5) and 34.1% (11.4–46.3) at 12 months, 50.0% (25.9–87.5) and 37.5% (25.9–77.4) at 15 months and 50.0% (25.9–87.5) and 66.7% (37.7–100) at 18 months. Factors associated with a higher risk of ADA development were: longer disease duration (1–3 vs. < 1 year; adalimumab: HR 3.0, 95% CI 1.0–8.7; infliximab: HR 2.7, 95% CI 1.1–6.8), moderate disease activity (DAS28 3.2–5.1 vs. < 3.2; adalimumab: HR 6.6, 95% CI 1.3–33.7) and lifetime smoking (infliximab: HR 2.7, 95% CI 1.2–6.3). The current study focusing on patients co-treated with methotrexate for more than 95% of them found a late occurrence of ADAs not previously observed, whereby the risk continued to increase over 18 months. Disease duration, DAS28 and lifetime smoking are clinical predictors of ADA development." @default.
• W2897747244 created "2018-10-26" @default.
• W2897747244 creator A5001241744 @default.
• W2897747244 creator A5008306352 @default.
• W2897747244 creator A5008811878 @default.
• W2897747244 creator A5012564728 @default.
• W2897747244 creator A5015032522 @default.
• W2897747244 creator A5017658298 @default.
• W2897747244 creator A5024484324 @default.
• W2897747244 creator A5026533671 @default.
• W2897747244 creator A5028148209 @default.
• W2897747244 creator A5036796328 @default.
• W2897747244 creator A5041150149 @default.
• W2897747244 creator A5042086006 @default.
• W2897747244 creator A5045188549 @default.
• W2897747244 creator A5047548196 @default.
• W2897747244 creator A5051196993 @default.
• W2897747244 creator A5052842332 @default.
• W2897747244 creator A5053172551 @default.
• W2897747244 creator A5056983959 @default.
• W2897747244 creator A5060232276 @default.
• W2897747244 creator A5061276624 @default.
• W2897747244 creator A5061588605 @default.
• W2897747244 creator A5062376327 @default.
• W2897747244 creator A5066716373 @default.
• W2897747244 creator A5072715151 @default.
• W2897747244 creator A5075509772 @default.
• W2897747244 creator A5077554218 @default.
• W2897747244 creator A5084980166 @default.
• W2897747244 creator A5088946190 @default.
• W2897747244 creator A5090448389 @default.
• W2897747244 date "2019-06-01" @default.
• W2897747244 modified "2023-10-16" @default.
• W2897747244 title "Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis" @default.
• W2897747244 cites W104029306 @default.
• W2897747244 cites W1586962881 @default.
• W2897747244 cites W1588728586 @default.
• W2897747244 cites W1976548137 @default.
• W2897747244 cites W1979325667 @default.
• W2897747244 cites W1982079188 @default.
• W2897747244 cites W1992628263 @default.
• W2897747244 cites W1994479450 @default.
• W2897747244 cites W2000905503 @default.
• W2897747244 cites W2012059967 @default.
• W2897747244 cites W2017883234 @default.
• W2897747244 cites W2021221854 @default.
• W2897747244 cites W2024527432 @default.
• W2897747244 cites W2038405618 @default.
• W2897747244 cites W2039804759 @default.
• W2897747244 cites W2052047947 @default.
• W2897747244 cites W2052876353 @default.
• W2897747244 cites W2067973725 @default.
• W2897747244 cites W2079590652 @default.
• W2897747244 cites W2096545621 @default.
• W2897747244 cites W2101168807 @default.
• W2897747244 cites W2110177517 @default.
• W2897747244 cites W2110732019 @default.
• W2897747244 cites W2110936138 @default.
• W2897747244 cites W2111046066 @default.
• W2897747244 cites W2119046820 @default.
• W2897747244 cites W2120017555 @default.
• W2897747244 cites W2120312043 @default.
• W2897747244 cites W2120393706 @default.
• W2897747244 cites W2123170396 @default.
• W2897747244 cites W2124227426 @default.
• W2897747244 cites W2129592053 @default.
• W2897747244 cites W2138002074 @default.
• W2897747244 cites W2142594414 @default.
• W2897747244 cites W2149065814 @default.
• W2897747244 cites W2153721587 @default.
• W2897747244 cites W2153950041 @default.
• W2897747244 cites W2154144521 @default.
• W2897747244 cites W2154716537 @default.
• W2897747244 cites W2156996668 @default.
• W2897747244 cites W2159198570 @default.
• W2897747244 cites W2160660666 @default.
• W2897747244 cites W2166771071 @default.
• W2897747244 cites W2168814191 @default.
• W2897747244 cites W2169448344 @default.
• W2897747244 cites W2272291172 @default.
• W2897747244 cites W2345830777 @default.
• W2897747244 cites W2534943173 @default.
• W2897747244 cites W2548044085 @default.
• W2897747244 cites W2725127520 @default.
• W2897747244 doi "https://doi.org/10.1016/j.semarthrit.2018.10.006" @default.
• W2897747244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30420245" @default.
• W2897747244 hasPublicationYear "2019" @default.
• W2897747244 type Work @default.
• W2897747244 sameAs 2897747244 @default.
• W2897747244 citedByCount "42" @default.
• W2897747244 countsByYear W28977472442019 @default.
• W2897747244 countsByYear W28977472442020 @default.
• W2897747244 countsByYear W28977472442021 @default.
• W2897747244 countsByYear W28977472442022 @default.
• W2897747244 countsByYear W28977472442023 @default.
• W2897747244 crossrefType "journal-article" @default.
• W2897747244 hasAuthorship W2897747244A5001241744 @default.
• W2897747244 hasAuthorship W2897747244A5008306352 @default.

• next